10-K: Canopy Growth Restates Financials, Reports FY26 Results

Canopy Growth Corporation has filed its Form 10-K for the fiscal year ended March 31, 2026, detailing financial restatements due to accounting errors related to share-settled warrants and reporting a reduced net loss compared to the prior year.

Summary

• Canopy Growth Corporation filed its Annual Report on Form 10-K for the fiscal year ended March 31, 2026.
• The company has restated its previously issued financial statements for fiscal years ended March 31, 2025 and 2024, and certain quarterly periods, due to non-cash technical errors in accounting for share-settled warrants denominated in U.S. dollars.
• Management identified a material weakness in internal control over financial reporting related to the classification of these warrants.
• For fiscal year 2026, net revenue increased by 6% to $284.6 million, while the net loss from continuing operations decreased by 49% to $262.9 million.
• Adjusted EBITDA improved to a loss of $20.2 million in fiscal 2026 from a loss of $23.5 million in fiscal 2025.
• The company completed the acquisition of MTL Cannabis Corp. in March 2026.
• Canopy Growth established new at-the-market (ATM) equity programs in August 2025 and completed its February 2025 ATM program, raising significant capital.
• The company entered into a new senior secured term loan facility of approximately $162.1 million in January 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the material weakness in internal controls, financial restatements, and continued net losses, despite some revenue growth and improved Adjusted EBITDA. The significant impairments and volatile fair value of investments also contribute to a cautious outlook.

Positives

• Net revenue increased by 6% to $284.6 million in fiscal year 2026 compared to fiscal year 2025.
• Net loss from continuing operations significantly decreased by 49% to $262.9 million in fiscal year 2026 compared to fiscal year 2025.
• Adjusted EBITDA loss improved to $20.2 million in fiscal year 2026 from $23.5 million in fiscal year 2025.
• The company strengthened its financial position by raising $374 million in equity and securing a new $150 million term loan in fiscal year 2026.
• The acquisition of MTL Cannabis Corp. is expected to enhance market presence and provide additional cultivation capacity.
• Canopy Growth is Canada's #1 medical cannabis provider by revenue.
• The company is focused on profitable scale in adult-use cannabis through its brand portfolio.

Negatives

• The company restated previously issued financial statements due to accounting errors related to share-settled warrants.
• A material weakness in internal control over financial reporting was identified.
• Gross margin percentage decreased to 24% in fiscal year 2026 from 30% in fiscal year 2025.
• Storz & Bickel segment revenue decreased by 14% in fiscal year 2026 compared to fiscal year 2025.
• The company incurred significant asset impairment and restructuring costs of $67.1 million in fiscal year 2026.
• The company has a history of net losses and negative operating cash flow.
• The fair value of the equity method investment in Canopy USA declined by 72% from June 30, 2024, to March 31, 2026.

Risks

• The restatement of prior financial statements and the material weakness in internal controls could negatively affect investor confidence and expose the company to additional risks.
• The company may not be able to achieve or maintain profitability and may continue to incur losses in the future.
• The company is in the early stages of developing global infrastructure in a new industry and is subject to many risks common in developing companies.
• The company has been and may in the future be required to write down intangible assets, including goodwill, due to impairment.
• The anticipated benefits of the strategy involving Canopy USA may not be realized, and the fair value of the equity method investment in Canopy USA is volatile.
• The company is subject to extensive regulation and licensing, and may not successfully comply with all applicable laws and regulations.
• Acreage and Wana may default on their debt obligations, potentially leading to a loss of investment and negative impacts on Canopy USA's business and the Company's U.S. strategy.
• The company is subject to risks related to the protection and enforcement of its intellectual property rights.

Future Outlook

The company's strategy focuses on building consumer brands within an asset-right model, driving efficiency, and expanding its global medical cannabis portfolio. Key pillars include maintaining leadership in Canadian medical cannabis, global vaporization through Storz & Bickel, focused growth in international medical markets, profitable scale in adult-use cannabis, leveraging its asset-right model for cultivation, and gaining unparalleled exposure to the expanding U.S. cannabis market through Canopy USA.

Management Comments

• "We are here to better lives through cannabis. We believe in the power of a plant not as a trend or commodity, but as a catalyst for elevating human potential."
• "We are making decisions for the long term, creating standards others will follow, and earning trust every day."
• "Our foundation is built on four enduring values: Leadership. Excellence. Trust. Innovation."
• "Our expansion plans into the United States rely upon the continued operations and success of Canopy USA and its subsidiaries and the anticipated benefits of the strategy involving Canopy USA is uncertain and may not be realized."
• "We have identified a material weakness in our internal control over financial reporting which could, if not remediated, adversely affect our ability to report our financial condition and results of operations in a timely and accurate manner, which may adversely affect investor confidence in our company and, as a result, the value of the Canopy Shares."

Industry Context

StockSavvy.ai notes that Canopy Growth's filing reflects the ongoing challenges and strategic shifts within the cannabis industry, including the impact of regulatory changes, market competition, and the need for financial restructuring. The company's focus on its core Canadian operations, international medical markets, and its U.S. strategy via Canopy USA highlights key industry trends.

Comparison to Industry Standards

• Canopy Growth's gross margin percentage of 24% for FY2026 is below the industry average for mature consumer packaged goods companies, but reflects the ongoing investment and restructuring within the cannabis sector.
• The company's net loss from continuing operations, while reduced, still indicates a path to profitability that is longer than many established CPG companies.
• The significant investment in Canopy USA positions the company to capitalize on the U.S. market, a key growth area for the industry, though regulatory uncertainties remain a factor for all players in this space.
• The company's efforts to manage debt and raise capital through ATM programs are common strategies employed by companies in high-growth, capital-intensive industries like cannabis, aiming to balance operational needs with financial stability.

Corporate Governance

Legal Proceedings

• Putative class action lawsuits alleging misrepresentations in disclosures have been filed against the Company and former officers in Ontario and British Columbia.
• The Ontario Superior Court of Justice granted leave to proceed with claims under the Securities Act against the Company and two former officers in the Dziedziejko action.
• The Company is subject to an ongoing investigation by the SEC related to the BioSteel Review, following voluntary self-reporting of accounting matters.
• The Company denies any alleged misconduct and liability in all noted court and arbitration proceedings and expects to vigorously defend the claims.

Related Party Transactions

• On April 18, 2024, Greenstar converted approximately C$81.2 million of principal amount of the CBI Note into 9,111,549 Exchangeable Shares.
• Concurrently, Greenstar and CBG Holdings LLC exchanged their Canopy Shares for Exchangeable Shares.
• As a result of these transactions, the CBG Group no longer holds Canopy Shares and holds 26,261,474 Exchangeable Shares as of June 11, 2026.

Stakeholder Impact

• Shareholders may experience continued volatility in share price due to industry factors and company-specific challenges, including the material weakness in internal controls.
• Creditors and lenders may be impacted by the company's debt levels and covenants, particularly the restrictions imposed by the Amendment to the Loan Agreement.
• Employees may be affected by ongoing restructuring efforts and the company's focus on cost discipline, although equity awards aim to retain key talent.
• Regulators, including the SEC and Canadian securities authorities, are actively involved due to the financial restatements and ongoing investigations.

Next Steps

• Remediate the material weakness in internal control over financial reporting.
• Continue to integrate the acquisition of MTL Cannabis Corp.
• Execute on the strategy to expand global medical cannabis and adult-use cannabis markets.
• Monitor and manage the U.S. strategy through Canopy USA, acknowledging its inherent uncertainties.
• Continue to manage debt obligations and explore financing opportunities to ensure liquidity.

Key Dates

Recommendation

While Canopy Growth has shown some operational improvements and strategic progress, the restatement of financials due to accounting errors and the identified material weakness in internal controls present significant concerns regarding financial reporting reliability and governance. The continued net losses and substantial asset impairments also weigh on the outlook. However, the company's capital raises and debt management indicate efforts to stabilize the financial position. The potential for U.S. market entry via Canopy USA remains a long-term catalyst, but regulatory hurdles and execution risks are substantial. Given the mixed signals of operational improvement against governance and financial reporting concerns, a 'hold' recommendation is appropriate, pending clearer evidence of sustained profitability and effective remediation of internal control deficiencies.

Keywords

Canopy Growth, SEC Filing, 10-K, Financial Restatement, Cannabis Industry, Fiscal Year 2026, Net Revenue, Net Loss, Adjusted EBITDA, Canopy USA, MTL Acquisition, ATM Program, Term Loan, Corporate Governance, Internal Controls